EUVIMEDEUVIMED entdecken
Klinische Studie (Phase I)Open Access · CC BY-NC-ND 4.0

Fc-optimized CD40 agonistic antibody elicits tertiary lymphoid structure formation and systemic antitumor immunity in metastatic cancer

Juan C Osorio, David A Knorr, Polina Weitzenfeld, Lucas Blanchard, Ning Yao, Maria Baez, Carlo Sevilla, Meghan DiLillo, Jahan Rahman, Ved P Sharma, Jacqueline Bromberg, Michael A Postow und 3 weitere

Cancer Cell · 2025-10 · 43 (10) · 1902-1916.e9

DOI: 10.1016/j.ccell.2025.07.013 ↗

Kurz gefasst

Klinische Studie (Phase I) in der Zeitschrift Cancer Cell, 2025-10. Verfasst von Juan C Osorio und 14 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA; Laboratory of Molecular Genetics and Immunology, Rockefeller…. Hauptthemen laut MEDLINE: CD40 Antigens, Tertiary Lymphoid Structures, Antibodies, Monoclonal, Immunoglobulin Fc Fragments. Die Arbeit wurde bisher 53-mal zitiert (Crossref) und nennt 56 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: NCI NIH HHS, NCATS NIH HHS, Breast Cancer Alliance.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

CD40 agonism enhances antitumor immunity but is limited by systemic toxicity and poor efficacy. Here, we present a phase 1 study (NCT04059588) of intratumoral (i.t.) 2141-V11, an Fc-engineered anti-CD40 agonistic antibody with enhanced binding to the inhibitory receptor FcγRIIB. Among 12 metastatic cancer patients, 2141-V11 was well tolerated without dose-limiting toxicities. Six patients experienced tumor reduction, including two complete responses in melanoma and breast cancer. 2141-V11 induced regression in injected and non-injected lesions, correlating with systemic CD8+ T cell activation and mature tertiary lymphoid structures (TLSs) in complete responders. In CD40/FcγRs humanized mice bearing orthotopic tumors, i.t. 2141-V11 promoted de novo TLS formation, facilitating i.t. CD8+ T cell effector responses independent of lymph node priming. The resulting local immune responses by 2141-V11 mediated abscopal antitumor effects and sustained immune memory. These findings demonstrate that i.t. 2141-V11 is safe and promotes immune-privileged tumor microenvironments that promote systemic and durable antitumor immunity.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

CD40 AntigensTertiary Lymphoid StructuresAntibodies, MonoclonalImmunoglobulin Fc FragmentsAnimalsHumansMiceFemaleCD8-Positive T-LymphocytesTumor MicroenvironmentMaleMiddle AgedXenograft Model Antitumor AssaysAgedNeoplasm MetastasisReceptors, IgG

Stichwörter der Autor:innen

CD40Fc receptorFcγRIIBantibody engineeringcancer immunotherapyclinical trialcomplete responsedendritic celltertiary lymphoid structures

Substanzen

CD40 AntigensAntibodies, MonoclonalImmunoglobulin Fc FragmentsReceptors, IgG

Autor:innen und Institutionen

  • Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA; Laboratory of Molecular Genetics and Immunology, Rockefeller University, New York, NY 10065, USA. Electronic address: osorioj@mskc…
  • Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA; Laboratory of Molecular Genetics and Immunology, Rockefeller University, New York, NY 10065, USA.
  • Laboratory of Molecular Genetics and Immunology, Rockefeller University, New York, NY 10065, USA.
  • Laboratory of Molecular Genetics and Immunology, Rockefeller University, New York, NY 10065, USA; Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.
  • Bio-Imaging Resource Center, Rockefeller University, New York, NY 10065, USA.
  • Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.

Förderung

  • NCI NIH HHS
  • NCATS NIH HHS
  • Breast Cancer Alliance
  • Arnold and Mabel Beckman Foundation
  • National Center for Advancing Translational Sciences
  • National Institutes of Health National Cancer Institute
  • Debra and Leon Black Family Foundation
  • National Institutes of Health

Zitieren

APA

Osorio, J. C., Knorr, D. A., Weitzenfeld, P., Blanchard, L., Yao, N., Baez, M., Sevilla, C., DiLillo, M., Rahman, J., Sharma, V. P., Bromberg, J., Postow, M. A., Ariyan, C., Robson, M. E., & Ravetch, J. V. (2025). Fc-optimized CD40 agonistic antibody elicits tertiary lymphoid structure formation and systemic antitumor immunity in metastatic cancer. Cancer Cell, 43(10), 1902-1916.e9. https://doi.org/10.1016/j.ccell.2025.07.013

Vancouver

Osorio JC, Knorr DA, Weitzenfeld P, Blanchard L, Yao N, Baez M, et al. Fc-optimized CD40 agonistic antibody elicits tertiary lymphoid structure formation and systemic antitumor immunity in metastatic cancer. Cancer Cell. 2025;43(10):1902-1916.e9. doi:10.1016/j.ccell.2025.07.013

BibTeX
@article{Osorio2025,
  author = {Osorio, Juan C and Knorr, David A and Weitzenfeld, Polina and Blanchard, Lucas and Yao, Ning and Baez, Maria and Sevilla, Carlo and DiLillo, Meghan and Rahman, Jahan and Sharma, Ved P and Bromberg, Jacqueline and Postow, Michael A and Ariyan, Charlotte and Robson, Mark E and Ravetch, Jeffrey V},
  title = {Fc-optimized CD40 agonistic antibody elicits tertiary lymphoid structure formation and systemic antitumor immunity in metastatic cancer},
  journal = {Cancer Cell},
  year = {2025},
  volume = {43},
  number = {10},
  pages = {1902--1916.e9},
  doi = {10.1016/j.ccell.2025.07.013}
}
Kostenlos starten →